NCT06420219 An Integrative Multi-Omic Characterization of Head and Neck Carcinogenesis, Progression and Recurrence
| NCT ID | NCT06420219 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Southern California |
| Condition | Head and Neck Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-03-25 |
| Primary Completion | 2028-03-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2024-03-25 with a primary completion date of 2028-03-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates the cell and biomarkers associated with the aggressive behavior of cancer.
Eligibility Criteria
Inclusion Criteria: * Diagnosis/disease status: New diagnosis of head and neck cancer * Allowable type and amount of prior therapy: No prior treatment * Age ≥ 18 years. * Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: * Patients who have had treatment of head and neck cancer
Contact & Investigator
Albert Y Han, MD
PRINCIPAL INVESTIGATOR
University of Southern California
Frequently Asked Questions
Who can join the NCT06420219 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Head and Neck Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06420219 currently recruiting?
Yes, NCT06420219 is actively recruiting participants. Contact the research team at sandy.tran@med.usc.edu for enrollment information.
Where is the NCT06420219 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT06420219 clinical trial?
NCT06420219 is sponsored by University of Southern California. The principal investigator is Albert Y Han, MD at University of Southern California. The trial plans to enroll 50 participants.